Hard Belly can be difficult for patients to accurately describe and often presents as general weight gain or obesity. Talk to your patients about what they’re feeling and conduct a physical exam to determine if they may be a candidate for treatment.
*Also known as excess abdominal fat.
†Based on inclusion criteria in clinical trials for tesamorelin for injection.
References: 1. Carleir RY, de Truchis P, Ronze S, et al. MRI of intra-abdominal fat and HIV-associated lipodystrophy: a case review. J Radiol. 2007;88:947-955. 2. Sethi JK, Vidal-Pulg AJ. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007;48:1253-1262. 3. Falutz J. Management of fat accumulation in patients with HIV infection. Curr HIV/AIDS Rep. 2011:8(3):200-208. 4. Carter M, Hughson G. Lipodystrophy. http://www.aidsmap.com/lipodystrophy/page/1045065/. Accessed April 28, 2017. 5. National Institutes of Health: AIDS info: guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. April 8, 2015. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 28, 2017. 6. Shuster A, Patlas M, Pinthus JH, et al. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012;85(1009):1-10. 7. Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab. 2008;93(8):2937-2945. 8. Scherzer R, Heymsfield SB, Lee D, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS. 2011;25(11):1405-1414. 9. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects in randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG study A5224s. Clin Infect Dis. 2011;53(2):185-196. 10. Chow D, Day L, Souza S, et al. Metabolic complications of HIV therapy. IAPAC Mon. 2006;12(9):302-317.